Chorzow

• Study to Evaluate the Efficacy and Safety of ATI-045 in Atopic Dermatitis Not authorised
  2024-520302-19-00 4 Atopic dermatitis
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Unknown
  2022-502779-40-99 5 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• "MetCool ACS"- Metformin "Cooling" Effect on metformin-naive Patients Treated with PCI because of Acute Coronary Syndrome Pending
  2024-516589-13-00 5 Acute coronary syndrome
• A phase II efficacy and safety study of cell-free circulating tumor DNA-guided commencement of second-line treatment in patients with DLBCL/ … Pending
  2024-518275-64-00 4 Diffuse large B-cell lymphomas (DLBCL, Diffuse large B-cell lymphoma)
• A Study to Learn How Different Amounts of the Study Intervention Called PF-07832837 are Tolerated and Act in the Body in Healthy Adults and … Pending
  2025-524150-34-00 1 Atopic Dermatitis
• BETRI-Prospective: Asthma control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 µg]) vs Single Inhaler ICS/LABA (200/ … Pending
  2025-524289-56-00 6 Asthma
• A study of LY4268989 in participants with Moderately to Severely Active Ulcerative Colitis (EMERALD-3) Recruiting
  2025-524404-29-00 4 2026-06-24 Ulcerative Colitis, Active Moderate
• Open-label Extension of KarXT + KarX-EC for Agitation in Alzheimer’s Disease Recruiting
  2024-519994-20-00 5 2026-06-01 Agitation Associated with Alzheimer’s Disease
• A Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease Recruiting
  2025-524001-33-00 4 2026-05-22 Graves’ Disease
• A Long-Term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older with Moderate to Severe Eczema Recruiting
  2023-509124-18-00 5 2025-12-19 Moderate-to-Severe Atopic Dermatitis
• RVU120 Rollover Study Recruiting
  2025-521673-14-00 4 2025-12-03 Relapsed / Refractory Metastatic or Advanced Solid Tumors
• Selective Treatment of Oral Povorcitinib Long-Term Rollover Study (STOP-LTR) Recruiting
  2024-520107-12-00 5 2025-09-03 Hidradenitis Suppurativa // Prurigo Nodularis // Vitiligo
• The AIRTIVITY TM Study: A study to find out whether BI 1291583 helps people with bronchiectasis Recruiting
  2024-518589-29-00 5 2025-08-21 Bronchiectasis
• An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients w … Recruiting
  2023-507853-13-00 4 2025-02-25 Ulcerative Colitis
• Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-2) Recruiting
  2022-500700-22-00 5 2023-05-25 Active Systemic Lupus Erythematosus (SLE)
• Treatment of infants under one year with acute lymphoblastic leukemia according to the Interfant-21 protocol Recruiting
  2022-502503-30-00 5 2022-12-15 Acute lymphoblastic leukemia
• An unblinded, multi-center study evaluating long-term treatment with Zanubrutinib (BGB-3111) regimens in patients with blood cancer in the l … Recruiting
  2024-511267-28-00 5 2021-02-17 B-cell malignancies
• Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight and Diabetes Recruiting
  2025-523510-87-00 5 2026-06-25 Obesity
• Efficacy and Safety of KAI-9531 compared with Semaglutide in Participants Living With Obesity Who Do Not Have Diabetes Recruiting
  2025-523511-11-00 5 2026-06-24 Obesity
• A study to learn if galvokimig is safe and works in adults with moderate to severe atopic dermatitis Recruiting
  2025-522578-35-00 4 2026-03-30 Atopic Dermatitis
• A Study to Learn About the Study Medicine Called Ritlecitinib in People With Hives Without a Known Cause Recruiting
  2025-522642-44-00 4 2026-03-18 CHRONIC SPONTANEOUS URTICARIA
• ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting
  2025-522960-34-00 5 2026-02-09 Established cardiovascular disease
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease. Recruiting
  2025-520612-34-00 5 2025-11-28 Agitation Associated with Alzheimer’s Disease
• A Phase 2b Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Graves' Disease Recruiting
  2025-521920-31-00 4 2025-11-21 Graves’ Disease

Showing 1–24 of 64 trials